Retroviral Integrase: Difference between revisions
From Proteopedia
Jump to navigationJump to search
David Canner (talk | contribs) No edit summary |
David Canner (talk | contribs) No edit summary |
||
| Line 4: | Line 4: | ||
HIV Integrase inhibitors: Raltegravir, marketed as Isentress is currently approved as a therapeutic inhibitor of HIV integrase. It was approved on October 12, 2007. | HIV Integrase inhibitors: Raltegravir, marketed as Isentress is currently approved as a therapeutic inhibitor of HIV integrase. It was approved on October 12, 2007. | ||
[See below for a table of antiretroviral drugs with trade name, company, patents, and notes.] | [See below for a table of antiretroviral drugs with trade name, company, patents, and notes.] | ||
==Integrase Mechanism of Action== | ==Integrase Mechanism of Action== | ||
